← Back to Patent Explorer
US4117151A Expired / Lapsed US ⏱️ 0.0 years remaining

Therapeutic sulfonamides

Assignee: Sanofi SA
•
Filing: 1977-03-02
•
Granted: 1978-09-26
•
Expires: 1997-03-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention is concerned with novel sulfonamide compounds of the general formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein Ar represents an optionally substituted phenyl group or a saturated heterocyclic group, Am represents a dialkylamino group or a saturated heterocyclic group, A represents a 3-benzofuryl or 3-benzo[b] thienyl group, substituted in the 2-position by a lower alkyl group and optionally substituted in the 5-position by a halogen atom or a lower alkoxy group, and n is the integer 2 or 3. Said compounds are effective for treating certain pathological or otherwise abnormal conditions of the heart and more particularly angina pectoris.

Inventors

  • 👤 Marcel Descamps
  • 👤 Charles Goldenberg

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 18:33
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/78; C07D307/79; C07D307/80; A; A61; A61P; A61P9/00; A61P9/08; A61P9/10; C07D333/00; C07D333/50; C07D333/52; C07D333/54; C07D333/56

Claims Analysis

Total Claims: 20
Claim 1
Independent Claim 81 words
A sulfonamide derivative corresponding to the formula: ##STR8## or a pharmaceutically acceptable acid addition salt thereof, wherein Ar represents phenyl, p-chlorophenyl, p-methylphenyl, p-methoxyphenyl, p-nitrophenyl, or pyridyl; Am represents a lower dialkylamino group, piperidino or 2-methyl-piperazino; A represents 3-benzofuryl or 3-benzothienyl substituted in the 2-position by a branched- or straight-chain alkyl group containing from 1 to 4 carbon atoms and optionally substituted in the 5-position by a halogen atom or a lower alkoxy group, and n is the integer 2 or 3.
Claim 2
Dependent Claim 81 words
A sulfonamide derivative corresponding to the formula: ##STR8## or a pharmaceutically acceptable acid addition salt thereof, wherein Ar represents phenyl, p-chlorophenyl, p-methylphenyl, p-methoxyphenyl, p-nitrophenyl, or pyridyl; Am represents a lower dialkylamino group, piperidino or 2-methyl-piperazino; A represents 3-benzofuryl or 3-benzothienyl substituted in the 2-position by a branched- or straight-chain alkyl group containing from 1 to 4 carbon atoms and optionally substituted in the 5-position by a halogen atom or a lower alkoxy group, and n is the integer 2 or 3.
Claim 3
Dependent Claim 8 words
2-n-Butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 4
Dependent Claim 8 words
2-n-Butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 5
Dependent Claim 8 words
2-n-Butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 6
Dependent Claim 8 words
2-n-Butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 7
Dependent Claim 8 words
2-n-Butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 8
Dependent Claim 8 words
2-n-Butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 9
Dependent Claim 8 words
2-n-Propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 10
Dependent Claim 8 words
2-n-Propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 11
Dependent Claim 8 words
2-Isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 12
Dependent Claim 8 words
2-Isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and pharmaceutically acceptable acid addition salts thereof.
Claim 13
Dependent Claim 49 words
A pharmaceutical or veterinary composition useful in treating pathological conditions of the heart and particularly angina pectoris, containing an active principle an effective amount of at least one compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutical excipient or carrier therefor.
Claim 14
Dependent Claim 49 words
A pharmaceutical or veterinary composition useful in treating pathological conditions of the heart and particularly angina pectoris, containing an active principle an effective amount of at least one compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutical excipient or carrier therefor.
Claim 15
Dependent Claim 58 words
A pharmaceutical or veterinary composition useful in treating pathological conditions of the heart and particularly angina pectoris, containing as active principle an effective amount of at least one compound selected from the group consisting of: 2-n-butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and 2-isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and the pharmaceutically acceptable acid addition salts thereof in association with a pharmaceutical excipient or carrier therefor.
Claim 16
Dependent Claim 58 words
A pharmaceutical or veterinary composition useful in treating pathological conditions of the heart and particularly angina pectoris, containing as active principle an effective amount of at least one compound selected from the group consisting of: 2-n-butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and 2-isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and the pharmaceutically acceptable acid addition salts thereof in association with a pharmaceutical excipient or carrier therefor.
Claim 17
Independent Claim 47 words
A method of treating pathological conditions of the heart and particularly angina pectoris in a subject in need of such treatment which method comprises administering to said subject an effective dose of at least one compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
Claim 18
Independent Claim 47 words
A method of treating pathological conditions of the heart and particularly angina pectoris in a subject in need of such treatment which method comprises administering to said subject an effective dose of at least one compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
Claim 19
Independent Claim 56 words
A method of treating pathological conditions of the heart and particularly angina pectoris in a subject in need of such treatment which method comprises administering to said subject an effective dose of at least one compound selected from the group consisting of: 2-n-butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and 2-isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and the pharmaceutically acceptable acid addition salts thereof.
Claim 20
Independent Claim 56 words
A method of treating pathological conditions of the heart and particularly angina pectoris in a subject in need of such treatment which method comprises administering to said subject an effective dose of at least one compound selected from the group consisting of: 2-n-butyl-3-[N-(2-dimethylaminoethyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-propylaminopropyl)-N-(4-nitro-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-butyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methoxy-benzenesulfonyl)-4-amino-benzoyl]-benzofuran 2-n-propyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and 2-isopropyl-3-[N-(3-di-n-butylaminopropyl)-N-(4-methyl-benzenesulfonyl)-4-amino-benzoyl]-benzofuran and the pharmaceutically acceptable acid addition salts thereof.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-09-25 1982-03-27 1982-09-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-09-25 1986-03-27 1986-09-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-09-25 1990-03-27 1990-09-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag